相关实验视频
Updated: Jun 13, 2026
06:55
Protocol to Create Chronic Wounds in Diabetic Mice
Published on: September 25, 2019
20.1K
6-生醇微针通过调节巨细胞两极分化促进糖尿病伤口愈合
Ling Yuan1, Qifeng He1, Yi Zhang2
1College of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China.
International immunopharmacology
|February 26, 2025
概括
这项研究引入了一种新的水凝微针系统 (6-G@MN),使用6-甘醇通过重新平衡巨细胞和促进组织修复来改善糖尿病伤口愈合.
科学领域:
- 生物医学工程 生物医学工程
- 伤口愈合 治愈 伤口愈合
- 糖尿病并发症 糖尿病并发症
背景情况:
- 糖尿病伤口愈合受高血糖症影响,这增加了M1巨细胞并延长了炎症.
- 准巨细胞两极分化是糖尿病伤口治疗的一个有希望的策略.
- 6 - 生醇 (6-G) 具有抗炎性质,但具有较差的溶解性和生物可用性.
研究的目的:
- 开发一种新型的水凝微针系统 (6-G@MN),用于增强6 - 甘醇 (6-G) 的输送.
- 评估6-G@MN在促进糖尿病伤口愈合方面的疗效.
- 调查潜在的机制,包括巨细胞两极分化和信号通路.
主要方法:
- 制造一个含有6-甘醇 (6-G) 的水凝微针系统.
- 在体外评估6-G对M1巨细胞两极分化的作用.
- 在糖尿病小鼠伤口模型中对6-G@MN的体内评估,评估血管生成,原沉积和巨细胞群.
- 对AMPK/mTOR信号通路的分析.
主要成果:
- 6-G@MN系统有效地提供了6-G,提高了溶解度和生物可用性.
- 6-G@MN显著促进了糖尿病伤口中的血管生成和原沉积.
- 治疗重新平衡了巨细胞种群,从M1转向抗炎性表型.
- 6-G抑制了脂聚糖诱导的M1巨细胞极化,并在体外激活了AMPK/mTOR通路.
结论:
- 6-G@MN代表了一种新的治疗策略,它结合了6-Gingerol和微针技术,用于糖尿病伤口愈合.
- 通过6-G@MN准巨细胞两极分化提供了一种有希望的方法来克服糖尿病伤口愈合的挑战.
- 该系统通过改善6G输送和调节炎症微环境来提高治疗结果.
相关概念视频
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...